Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Anaplastic Astrocytoma
- Anaplastic Oligoastrocytoma
- Brain Cancer
- Brain Neoplasm
- Brain Neoplasm, Malignant
- Brain Tumor
- Brain Tumor Recurrent
- Glioblastoma
- Glioma
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT02800486
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: John Boockvar, MD Northwell Health